Acorda Therapeutics to Present an Overview of its Preclinical Pipeline at Windhover Therapeutic Area Partnerships Conference.HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR ACOR Association of Cancer Online Resources ACOR American Center of Oriental Research ACOR Advanced Certificate in Operational Risk ACOR Assistant Contracting Officer Representative ACOR Actual Cost of Repair ACOR Administrative Contracting Officers Representative ) today announced that Anthony Caggiano M.D., Ph.D., Senior Director, Preclinical Development, will present an overview of the Company's preclinical pipeline at the Windhover Therapeutic Area Partnerships Conference on Tuesday, November 4, 2008 at 3:50 p.m. ET at the Loews Philadelphia Hotel in Philadelphia, PA. The Acorda preclinical pipeline has been selected by Windhover Information as one of the top 10 most interesting neuroscience projects in development available for strategic partnering. Acorda's preclinical pipeline comprises three programs: a monoclonal antibody (rhIgM22), being studied in collaboration with Mayo Clinic for the regeneration of myelin myelin /my·elin/ (mi´e-lin) the lipid-rich substance of the cell membrane of Schwann cells that coils to form the myelin sheath surrounding the axon of myelinated nerve fibers. on nerve fibers damaged by multiple sclerosis (MS); a family of proteins called neuregulins being studied in various therapeutic applications for both neurological and cardiac diseases, including MS, stroke and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. ; and chondroitinase, a bacterial enzyme being studied for repair of nerve connections in spinal cord and brain injuries. Acorda plans to file Investigational New Drug (IND) applications in late 2009 for rhIgM22 and GGF GGF Gegebenenfalls (German: if necessary) GGF Geschäftsführer (German) GGF Global Grid Forum GGF Glass and Glazing Federation (UK) GGF Great-Grandfather GGF Good Good Friday 2, the Company's lead neuregulin molecule, pending results of toxicology studies. About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , multiple sclerosis and related nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's marketed products include Zanaflex Capsules([R]) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. In June 2008, Acorda's lead clinical product, Fampridine-SR, completed a second Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including delays in obtaining or failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Fampridine-SR, the risk of unfavorable results from future studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market and sell Fampridine-SR, if approved, and Zanaflex Capsules, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion